Open Access

Upregulation of microRNA-32 is associated with tumorigenesis and poor prognosis in patients with hepatocellular carcinoma

  • Authors:
    • Huiqiong Yang
    • Yusheng Li
    • Xiaoming Zhong
    • Pei Luo
    • Ping Luo
    • Ran Sun
    • Ruting Xie
    • Da Fu
    • Yushui Ma
    • Xianling Cong
    • Wenping Li
  • View Affiliations

  • Published online on: January 26, 2018     https://doi.org/10.3892/ol.2018.7879
  • Pages: 4097-4104
  • Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

MicroRNA-32 (miR-32) is associated with tumor progression and poor prognosis in certain malignant tumors. However, the function and clinical relevance of miR‑32 in human hepatocellular carcinoma (HCC) has not yet been elucidated. The present study aimed to investigate the expression and prognostic value of miR‑32 from liver samples in patients with HCC. The expression of miR‑32 was analyzed in HCC and healthy tissues using Gene Expression Omnibus datasets. Reverse transcription‑quantitative polymerase chain reaction was used to analyze the levels of miR‑32 mRNA in 154 HCC liver samples, 33 of which were paired with adjacent non‑tumor tissues. The overall survival (OS) rate in patients with HCC was evaluated using Kaplan‑Meier survival analysis, and the factors that may affect the prognosis and survival of patients with HCC were analyzed using univariate (log‑rank test) and multivariate Cox proportional hazard models. The present results demonstrated that miR‑32 expression levels were significantly upregulated in HCC liver biopsies compared with normal tissues (P<0.05). miR‑32 expression was significantly associated with the number of foci and tumor diameter (P<0.05). In addition, Kaplan‑Meier analysis revealed that patients with low miR‑32 expression had longer OS and disease‑free survival compared with those with high miR‑32 expression (P<0.01). Altogether, to the best our knowledge, the present study is the first study to indicate the association between increased miR‑32 expression with HCC progression and poor prognosis in patients. This suggests that miR‑32 may have potential prognostic value and may be used as a tumor biomarker for the diagnosis of patients with HCC.

References

1 

Wang Y, Ma Y, Fang Y, Wu S, Liu L, Fu D and Shen X: Regulatory T cell: A protection for tumor cells. J Cell Mol Med. 16:425–436. 2012. View Article : Google Scholar : PubMed/NCBI

2 

Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. Ca Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI

3 

Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI

4 

Fang Y, Fu D, Tang WQ, Cai Y, Ma D, Wang HJ, Xue RY, Liu TT, Huang XW, Dong L, et al: Ubiquitin C-terminal hydrolase 37, a novel predictor for hepatocellular carcinoma recurrence, promotes cell migration and invasion via interacting and deubiquitinating PRP19. Biochim Biophys Acta. 1833:559–572. 2013. View Article : Google Scholar : PubMed/NCBI

5 

Chen YJ, Ma YS, Fang Y, Wang Y, Fu D and Shen XZ: Power and promise of ubiquitin carboxyl-terminal hydrolase 37 as a target of cancer therapy. Asian Pac J Cancer Prev. 14:2173–2179. 2013. View Article : Google Scholar : PubMed/NCBI

6 

Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI

7 

Liu LL, Fu D, Ma Y and Shen XZ: The power and the promise of liver cancer stem cell markers. Stem Cells Dev. 20:2023–2030. 2011. View Article : Google Scholar : PubMed/NCBI

8 

Hou LK, Ma YS, Han Y, Lu GX, Luo P, Chang ZY, Xie RT, Yang HQ, Chai L, Cai MX, et al: Association of microRNA-33a molecular signature with non-small cell lung cancer diagnosis and prognosis after chemotherapy. PLoS One. 12:e01704312017. View Article : Google Scholar : PubMed/NCBI

9 

Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI

10 

Cho WC: OncomiRs: The discovery and progress of microRNAs in cancers. Mol Cancer. 6:602007. View Article : Google Scholar : PubMed/NCBI

11 

Jay C, Nemunaitis J, Chen P, Fulgham P and Tong AW: miRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol. 26:293–300. 1007. View Article : Google Scholar

12 

Wu W, Yang J, Feng X, Wang H, Ye S, Yang P, Tan W, Wei G and Zhou Y: MicroRNA-32 (miR-32) regulates phosphatase and tensin homologue (PTEN) expression and promotes growth, migration, and invasion in colorectal carcinoma cells. Mol Cancer. 12:302013. View Article : Google Scholar : PubMed/NCBI

13 

Fang Y, Fu D and Shen XZ: The potential role of ubiquitin C-terminal hydrolases in oncogenesis. Biochim Biophys Acta. 1806:1–6. 2010.PubMed/NCBI

14 

Jalava SE, Urbanucci A, Latonen L, Waltering KK, Sahu B, Jänne OA, Seppälä J, Lähdesmäki H, Tammela TL and Visakorpi T: Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer. Oncogene. 31:4460–4471. 2012. View Article : Google Scholar : PubMed/NCBI

15 

Bai Y, Wang YL, Yao WJ, Guo L, Xi HF, Li SY and Zhao BS: Expression of miR-32 in human non-small cell lung cancer and its correlation with tumor progression and patient survival. Int J Clin Exp Pathol. 8:824–829. 2015.PubMed/NCBI

16 

Xu JQ, Zhang WB, Wan R and Yang YQ: MicroRNA-32 inhibits osteosarcoma cell proliferation and invasion by targeting Sox9. Tumor Biol. 35:9847–953. 2014. View Article : Google Scholar

17 

Zhang J, Kuai X, Song M, Chen X, Yu Z, Zhang H and Mao Z: microRNA32 inhibits the proliferation and invasion of the SGC-7901 gastric cancer cell line in vitro. Oncol Lett. 7:270–274. 2014. View Article : Google Scholar : PubMed/NCBI

18 

Zhang D, Ni Z and Xu X: Decreased microRNA-32 in oral squamous cell carcinoma. Med Sci Monit. 20:2527–2535. 2014.PubMed/NCBI

19 

Yan SY, Chen MM, Li GM, Wang YQ and Fan JG: miR-32 induces cell proliferation, migration, and invasion in hepatocellular carcinoma by targeting PTEN. Tumor Biol. 36:4747–4755. 2015. View Article : Google Scholar

20 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

21 

Fang Y, Mu J, Ma Y, Ma D, Fu D and Shen X: The interaction between ubiquitin C-terminal hydrolase 37 and glucose-regulated protein 78 in hepatocellular carcinoma. Mol Cell Biochem. 359:59–66. 2012. View Article : Google Scholar : PubMed/NCBI

22 

Ma YS, Wu TM, Lv ZW, Lu GX, Cong XL, Xie RT, Yang HQ, Chang ZY, Sun R, Chai L, et al: High expression of miR-105-1 positively correlates with clinical prognosis of hepatocellular carcinoma by targeting oncogene NCOA1. Oncotarget. 8:11896–11905. 2017.PubMed/NCBI

23 

Wu SD, Ma YS, Fang Y, Liu LL, Fu D and Shen XZ: Role of the microenvironment in hepatocellular carcinoma development and progression. Cancer Treat Rev. 38:218–225. 2012. View Article : Google Scholar : PubMed/NCBI

24 

Ge S and Huang D: Systemic therapies for hepatocellular carcinoma. Drug Discov Ther. 9:352–362. 2015. View Article : Google Scholar : PubMed/NCBI

25 

Bartels CL and Tsongalis GJ: MicroRNAs: Novel biomarkers for human cancer. Ann Biol Clin (Paris). 68:263–272. 2010.(In French). PubMed/NCBI

26 

Ma Y, Hou L, Yu F, Lu G, Qin S, Xie R, Yang H, Wu T, Luo P, Chai L, et al: Incidence and physiological mechanism of carboplatin-induced electrolyte abnormality among patients with non-small cell lung cancer. Oncotarget. 8:18417–18423. 2017.PubMed/NCBI

27 

Li LM, Hu ZB, Zhou ZX, Chen X, Liu FY, Zhang JF, Shen HB, Zhang CY and Zen K: Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res. 70:9798–9807. 2010. View Article : Google Scholar : PubMed/NCBI

28 

Sukata T, Sumida K, Kushida M, Ogata K, Miyata K, Yabushita S and Uwagawa S: Circulating microRNAs, possible indicators of progress of rat hepatocarcinogenesis from early stages. Toxicol Lett. 200:46–52. 2011. View Article : Google Scholar : PubMed/NCBI

29 

Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, Mazzaferro V, Lowe SW, Croce CM and Dejean A: miR-221 overexpression contributes to liver tumorigebesis. Proc Natl Acad Sci USA. 107:pp. 264–269. 2010; View Article : Google Scholar : PubMed/NCBI

30 

Wang X, Zhu Y, Ma Y, Wang J, Zhang F, Xia Q and Fu D: The role of cancer stem cells in cancer metastasis: New perspective and progress. Cancer Epidemiol. 37:60–63. 2013. View Article : Google Scholar : PubMed/NCBI

31 

Zhu D, Chen H, Yang X, Chen W, Wang L, Xu J and Yu L: miR-32 functions as a tumor suppressor and directly targets SOX9 in human non-small cell lung cancer. Onco Targets Ther. 8:1773–1783. 2015. View Article : Google Scholar : PubMed/NCBI

32 

Wu W, Yang P, Feng X, Wang H, Qiu Y, Tian T, He Y, Yu C, Yang J, Ye S and Zhou Y: The relationship between and clinical significance of MicroRNA-32 and phosphatase and tensin homologue expression in colorectal cancer. Genes Chromosomes Cancer. 52:1133–1140. 2013. View Article : Google Scholar : PubMed/NCBI

33 

Wang H, Xu T, Jiang Y, Xu H, Yan Y, Fu D and Chen J: The challenges and the promise of molecular targeted therapy in malignant gliomas. Neoplasia. 17:239–255. 2015. View Article : Google Scholar : PubMed/NCBI

34 

Sato F, Hatano E, Kitamura K, Myomoto A, Fujiwara T, Takizawa S, Tsuchiya S, Tsujimoto G, Uemoto S and Shimizu K: MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan Criteria. PLoS One. 6:e164352011. View Article : Google Scholar : PubMed/NCBI

35 

Burchard J, Zhang C, Liu AM, Poon RT, Lee NP, Wong KF, Sham PC, Lam BY, Ferguson MD, Tokiwa G, et al: microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma. Mol Syst Biol. 6:4022010. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

April 2018
Volume 15 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yang, H., Li, Y., Zhong, X., Luo, P., Luo, P., Sun, R. ... Li, W. (2018). Upregulation of microRNA-32 is associated with tumorigenesis and poor prognosis in patients with hepatocellular carcinoma. Oncology Letters, 15, 4097-4104. https://doi.org/10.3892/ol.2018.7879
MLA
Yang, H., Li, Y., Zhong, X., Luo, P., Luo, P., Sun, R., Xie, R., Fu, D., Ma, Y., Cong, X., Li, W."Upregulation of microRNA-32 is associated with tumorigenesis and poor prognosis in patients with hepatocellular carcinoma". Oncology Letters 15.4 (2018): 4097-4104.
Chicago
Yang, H., Li, Y., Zhong, X., Luo, P., Luo, P., Sun, R., Xie, R., Fu, D., Ma, Y., Cong, X., Li, W."Upregulation of microRNA-32 is associated with tumorigenesis and poor prognosis in patients with hepatocellular carcinoma". Oncology Letters 15, no. 4 (2018): 4097-4104. https://doi.org/10.3892/ol.2018.7879